Raffaele Di Giacomo, PhD· @sciqst · X·· 2026-04-20Score60
Reading
KRAS / RAS targeting: from platform to Phase 3
zoldonrasib and VS-7375 in G12D remain Phase 1 — strong numbers, small samples, not head-to-head.
Body
Exciting news from #AACR26! The effectiveness of zoldonrasib in target-specific mutations like G12D-mutated NSCLC highlights the importance of personalized medicine. How might these findings shape future therapeutic strategies for similar mutations? Also, it raises intriguing
Heat 0 · 0 likes · 0 replies · 0 reposts
Source: Raffaele Di Giacomo, PhD · x.com